Impact of hemodialysis therapy on hepatitis C virus infection: A deeper insight

Research output: Contribution to journalArticle

Abstract

Hepatitis C Virus (HCV) infection remains prevalent in patients receiving regular dialysis all over the world. The adverse impact of anti-HCV serologic status on mortality in the dialysis population has been documented. Antiviral therapy for hepatitis C in chronic kidney disease (CKD) patients, including the dialysis population, is still unsatisfactory. Several findings support a different course of HCV in dialysis patients versus the non-uremic population. The HCV viral load appears lower in hemodialysis patients with HCV despite the immune compromise caused by chronic uremia; the histologic abnormalities seem milder, and a severe clinical course of chronic hepatitis C is unusual in most hemodialysis (HD) patients. It appears that the HD procedure per se can preserve patients from an aggressive course of HCV by reducing the viral load (HCV RNA). The mechanisms by which the HD procedure lowers HCV viremia remain largely speculative: the passage of viral particles into the dialysate, the trapping of the virus on the surface of the dialyzer membrane, and an indirect host-mediated mechanism have been cited. The latter hypothesis implicates the production of interferon-α, hepatocyte growth factor, or other cytokines provided with antiviral activities during the hemodialysis sessions. Clinical trials aimed at clarifying this issue are under way.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalInternational Journal of Artificial Organs
Volume32
Issue number1
Publication statusPublished - 2009

Fingerprint

Virus Diseases
Viruses
Hepacivirus
Renal Dialysis
Dialysis
Therapeutics
Viral Load
Antiviral Agents
Population
Interferons
Hepatocyte Growth Factor
Uremia
Viremia
Dialysis Solutions
Chronic Hepatitis C
Hepatitis C
Chronic Renal Insufficiency
Virion
RNA
Clinical Trials

Keywords

  • Dialysis
  • HCV viremia
  • Hepatitis C virus
  • Natural history

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Bioengineering
  • Medicine (miscellaneous)

Cite this

Impact of hemodialysis therapy on hepatitis C virus infection : A deeper insight. / Fabrizi, Fabrizio; Messa, P.; Martin, P.

In: International Journal of Artificial Organs, Vol. 32, No. 1, 2009, p. 1-11.

Research output: Contribution to journalArticle

@article{6781e53f3d46408eb7b3d19b49fa6b88,
title = "Impact of hemodialysis therapy on hepatitis C virus infection: A deeper insight",
abstract = "Hepatitis C Virus (HCV) infection remains prevalent in patients receiving regular dialysis all over the world. The adverse impact of anti-HCV serologic status on mortality in the dialysis population has been documented. Antiviral therapy for hepatitis C in chronic kidney disease (CKD) patients, including the dialysis population, is still unsatisfactory. Several findings support a different course of HCV in dialysis patients versus the non-uremic population. The HCV viral load appears lower in hemodialysis patients with HCV despite the immune compromise caused by chronic uremia; the histologic abnormalities seem milder, and a severe clinical course of chronic hepatitis C is unusual in most hemodialysis (HD) patients. It appears that the HD procedure per se can preserve patients from an aggressive course of HCV by reducing the viral load (HCV RNA). The mechanisms by which the HD procedure lowers HCV viremia remain largely speculative: the passage of viral particles into the dialysate, the trapping of the virus on the surface of the dialyzer membrane, and an indirect host-mediated mechanism have been cited. The latter hypothesis implicates the production of interferon-α, hepatocyte growth factor, or other cytokines provided with antiviral activities during the hemodialysis sessions. Clinical trials aimed at clarifying this issue are under way.",
keywords = "Dialysis, HCV viremia, Hepatitis C virus, Natural history",
author = "Fabrizio Fabrizi and P. Messa and P. Martin",
year = "2009",
language = "English",
volume = "32",
pages = "1--11",
journal = "International Journal of Artificial Organs",
issn = "0391-3988",
publisher = "Wichtig Publishing",
number = "1",

}

TY - JOUR

T1 - Impact of hemodialysis therapy on hepatitis C virus infection

T2 - A deeper insight

AU - Fabrizi, Fabrizio

AU - Messa, P.

AU - Martin, P.

PY - 2009

Y1 - 2009

N2 - Hepatitis C Virus (HCV) infection remains prevalent in patients receiving regular dialysis all over the world. The adverse impact of anti-HCV serologic status on mortality in the dialysis population has been documented. Antiviral therapy for hepatitis C in chronic kidney disease (CKD) patients, including the dialysis population, is still unsatisfactory. Several findings support a different course of HCV in dialysis patients versus the non-uremic population. The HCV viral load appears lower in hemodialysis patients with HCV despite the immune compromise caused by chronic uremia; the histologic abnormalities seem milder, and a severe clinical course of chronic hepatitis C is unusual in most hemodialysis (HD) patients. It appears that the HD procedure per se can preserve patients from an aggressive course of HCV by reducing the viral load (HCV RNA). The mechanisms by which the HD procedure lowers HCV viremia remain largely speculative: the passage of viral particles into the dialysate, the trapping of the virus on the surface of the dialyzer membrane, and an indirect host-mediated mechanism have been cited. The latter hypothesis implicates the production of interferon-α, hepatocyte growth factor, or other cytokines provided with antiviral activities during the hemodialysis sessions. Clinical trials aimed at clarifying this issue are under way.

AB - Hepatitis C Virus (HCV) infection remains prevalent in patients receiving regular dialysis all over the world. The adverse impact of anti-HCV serologic status on mortality in the dialysis population has been documented. Antiviral therapy for hepatitis C in chronic kidney disease (CKD) patients, including the dialysis population, is still unsatisfactory. Several findings support a different course of HCV in dialysis patients versus the non-uremic population. The HCV viral load appears lower in hemodialysis patients with HCV despite the immune compromise caused by chronic uremia; the histologic abnormalities seem milder, and a severe clinical course of chronic hepatitis C is unusual in most hemodialysis (HD) patients. It appears that the HD procedure per se can preserve patients from an aggressive course of HCV by reducing the viral load (HCV RNA). The mechanisms by which the HD procedure lowers HCV viremia remain largely speculative: the passage of viral particles into the dialysate, the trapping of the virus on the surface of the dialyzer membrane, and an indirect host-mediated mechanism have been cited. The latter hypothesis implicates the production of interferon-α, hepatocyte growth factor, or other cytokines provided with antiviral activities during the hemodialysis sessions. Clinical trials aimed at clarifying this issue are under way.

KW - Dialysis

KW - HCV viremia

KW - Hepatitis C virus

KW - Natural history

UR - http://www.scopus.com/inward/record.url?scp=64849110263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64849110263&partnerID=8YFLogxK

M3 - Article

C2 - 19241358

AN - SCOPUS:64849110263

VL - 32

SP - 1

EP - 11

JO - International Journal of Artificial Organs

JF - International Journal of Artificial Organs

SN - 0391-3988

IS - 1

ER -